

***In vivo* quantification of nanoparticle association with immune cell subsets in blood**

Yih Rue Ong, Robert De Rose, Angus Johnston*

((Optional Dedication))

Y. R. Ong, Dr. R. De Rose, Dr. A. Johnston

1) Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.

2) ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, VIC, Australia.

E-mail: angus.johnston@monash.edu

Keywords: immunology, nanoparticle, blood association, *ex vivo*, *in vivo*

Nanoparticles offer great promise for more effective drug delivery. However, their particulate nature typically results in rapid systemic clearance by immune cells in blood. Currently, to understand these interactions, nanoparticle association is probed *ex vivo* with whole blood. While *ex vivo* assays give important information about the relative cell association, they do not consider changes in immune cell homeostasis or the complex mixing behavior that occurs *in vivo*. To address this, we developed a Nanoparticle In Vivo Immune-cell Association (NIVIA) assay to study the *in vivo* association of unmodified and PEGylated liposomes with immune cells, and compared this to the *ex vivo* association in static whole blood. *In vivo*, we observed that neutrophils play a significantly greater role in nanoparticle binding than suggested by *ex vivo* assays. The increased influence of neutrophils *in vivo* was largely due to a significant increase in number of circulating neutrophils after intravenous injection. Conversely, the number of circulating monocytes significantly decreased after intravenous injection, leading to significantly less total association of liposomes to monocytes compared to *ex vivo*. This novel *in vivo* immune cell binding assay sheds new light on the fate of nanoparticles following intravenous delivery.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/adhm.202002160](https://doi.org/10.1002/adhm.202002160).

This article is protected by copyright. All rights reserved.

Introduction

Nanoparticles are increasingly being used for medical applications as carriers to transport drugs to sites of interest (e.g. tumor), for diagnostic purposes and for vaccine applications.^[1-3] For many applications, nanoparticles will be administered intravenously.^[4] A significant impediment for intravenous delivery is that nanoparticles are readily identified as foreign bodies by the innate immune system and can undergo rapid systemic clearance. Exposure to blood results in plasma proteins adsorbing on the surface of the nanoparticles, referred to as the protein corona, which modifies the physicochemical properties of the nanoparticle and opsonizes the particles for phagocytosis and removal from circulation.^[5] The role of the protein corona has been studied by incubating nanoparticles in solutions containing multiple protein components from serum and plasma.^[6, 7] Modifications to the surface of the nanoparticles, including the low-fouling hydrophilic polymer poly(ethylene glycol) (PEG), are commonly used to limit opsonization and improve delivery to the site of action.^[8] However, it is hard to predict how these modifications modulate protein interactions, as protein adsorption is governed by density, length and conformation of the surface coating, as well as the properties of the underlying nanoparticle. Therefore, it is important to investigate how nanoparticles, and any modifications made to them, influence binding to cells.

In vitro assays have been used to assess the phagocytic ability of cultured macrophages or dendritic cells following nanoparticle exposure.^[9, 10] However, these *in vitro* studies do not account for all plasma proteins nor the many different types of cells in blood. Blood is composed of erythrocytes, platelets, leukocytes and plasma. Capture of nanoparticles typically occurs by leukocytes through phagocytic and non-phagocytic mechanisms. In blood, the phagocytic cells are monocytes, neutrophils, eosinophils and dendritic cells that, on a per cell basis, have the greatest capacity to

This article is protected by copyright. All rights reserved.

remove nanoparticles from circulation. Nanoparticles can also adhere to B cells, T cells and NK cells that make up the pool of lymphocytes, but these cells have a comparatively limited capacity to internalize particles, which theoretically reduces their role in nanoparticle capture.^[11] By incubating nanoparticles in whole blood, the complex interaction of nanoparticles with all the components of blood are taken into consideration. Currently, the gold standard for evaluation of nanoparticle interactions with blood is an *ex vivo* whole blood assay.

The *ex vivo* blood assay is a quick and simple surrogate for evaluating the initial complex interplay of nanoparticle interactions with plasma protein and cells following intravenous injection.^[12]

Nanoparticles are also subjected to complex mixing within blood vessels that changes as the particles move successively through arteries with high velocity flow, to capillaries within tissues where flow is dramatically reduced and then into veins. The influence of all these factors on nanoparticle sequestration in blood can therefore only be captured by evaluating the cellular interactions *in vivo*.

A limited number of preclinical *in vivo* studies have quantified the association of nanoparticles with immune cells in blood through flow cytometry, but these studies only looked at interactions with specific subsets of cells.^[13-15] These were principally performed with antibodies against the common leukocyte antigen CD45, or a single immune cell subset of interest (e.g. neutrophils). In this study, we expanded upon the current understanding of nanoparticle-immune cell interactions in the blood by developing a Nanoparticle In Vivo Immune-cell Association (NIVIA) assay to probe nanoparticle interactions with all immune cell subsets *in vivo*, and directly compared these interactions to nanoparticles incubated with whole blood *ex vivo*. Unmodified phosphatidylcholine liposomes and PEGylated phosphatidylcholine liposomes, which have similar formulations to clinical therapies (Myocet and Doxil respectively, but without the doxorubicin) were used in this evaluation.

Results

To probe for differences between *in vivo* and *ex vivo* nanoparticle-immune cell interactions, we compared nanoparticle association with immune cells in blood following *in vivo* administration to mice (NIVIA), to nanoparticles incubated in whole mouse blood *ex vivo*. Immune cells were identified by labeling with a cocktail of antibodies (**Table S1**). The two types of phosphatidylcholine (PC) liposomes used in this study – unmodified liposomes (referred to from herein as PC liposomes) and PC liposomes modified with ~5 mol % 2000 MW polyethylene glycol (PEG-liposomes) are similar to clinical liposomal formulations Myocet and Doxil respectively. Both types of liposomes were fluorescently labeled with a lipophilic dye, DiD, that inserts into the liposome membrane.^[16] The mean (\pm SD) particle sizes were 116 ± 26 nm for PC liposomes and 127 ± 30 nm for PEG-liposomes (**Figure S1**). The zeta potential for PC liposomes (-7 ± 9 mV) and PEG-liposomes (-11 ± 7 mV) were similar. The negative charge was expected due to the presence of a small amount of the negatively charged 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) in each formulation.

To match the concentration of liposomes to immune cells in the *ex vivo* and *in vivo* experiments, the *ex vivo* dose of liposomes was calculated based on the assumption that the total blood volume was 7% of the body weight of the mouse (70 mL/kg).^[17] The experimental steps for the NIVIA and *ex vivo* blood assay are outlined in **Figure 1**. Liposome interactions with immune cells were quantified using flow cytometry by evaluating the DiD signal associated with different immune cell subsets (**Figure S2**). The fluorescence intensity of PEG-liposomes was 59% brighter than unmodified liposomes (**Figure S3a**). To take this into account, the MFI of the PC liposomes was multiplied by 1.59. The endotoxin level of all liposome batches and PBS used in this study was indicated by manufacturers to be < 0.1 EU/mg and therefore comparable to levels in approved human therapies.

This article is protected by copyright. All rights reserved.




Figure 1. Flow diagram of the Nanoparticle In Vivo Immune- cell Association (NIVIA) assay and ex vivo blood assay. a) In the NIVIA assay, nanoparticles are injected into the tail vein of mice. b) After 1 hour, 100 μ l of blood (containing nanoparticles) is taken from the mice via a cheek bleed. c) For ex vivo blood association, blood is collected from the mouse, and then d) nanoparticles are mixed with the blood for 1 hour. e) For both assays after the 1 hour incubation, red blood cells are removed by lysis. f) Different populations of white blood cells are identified by adding a phenotyping cocktail of antibodies. g) Finally, cells are analysis using flow cytometry.

Association of liposomes to a minor blood subset (such as NK cells) will have less impact on blood clearance than the equivalent association with a major blood subset (such as B cells). Therefore, to determine which immune cell subsets significantly influence clearance of liposome from the blood, we calculated a parameter: ‘total association’. The ‘total association’ of each immune cell subset was calculated by multiplying the number of cells in each subset (relative to the number of T cells) by the background- subtracted MFI.

T cells were chosen as a reference cell population as the proportion of T cells in the CD45+ population (excluding monocytes and neutrophils) remained unchanged *in vivo* following intravenous injection (Figure S3b). Neutrophils and monocytes were excluded as they share complex relationship with each other in regulating the immune system.^[18] Detailed interactions of the different immune cell

subsets with PC-liposomes and PEG-liposomes are detailed in Figures 2 and 3 respectively. A simplified overview of the total association is summarized in Figure 4.

Association of PC liposomes with immune cells in blood

PC liposomes showed high association with monocytes both *in vivo* and *ex vivo* in whole blood (**Figure 2a-b**), however they showed lower association to monocytes *in vivo* compared to *ex vivo*, with 1.8x lower mean fluorescent intensity (MFI) ($p < 0.001$) (Figure 2c). The ratio of monocytes:T cells decreased 1h after the *in vivo* administration of PC liposomes (Figure 2d), although the significance ($p = 0.1$) was greater than the confidence limit. This phenomenon was also observed with the injection of PBS only (**Figure S4a**). The reduced number of monocytes, combined with the decreased number of PC liposomes per cell resulted in 5x lower total association of PC liposomes with monocytes *in vivo* compared to *ex vivo* (Figure 2e).




Figure 2. Association of PC liposomes with (a-e) monocytes, (f-j) neutrophils and (k-o) B cells. (a, f, k) Representative overlay histograms of control (green), ex vivo (red) and in vivo (blue) experiments. (b,g,l) Percentage of NP+ cells. (c, h, m) Corrected geometric mean fluorescent intensity (MFI) of sample minus the average MFI of the PBS. (d, i, n) Proportion of cells to T cells before and after administration of liposomes. (e, j, o) Total association of nanoparticles associated with the cells

between *ex vivo* and *in vivo* experiments. Bars depict mean values. * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$

At a cellular level, PC liposomes had 80x lower association with neutrophils (Figure 2h) than monocytes (Figure 2c). However, in contrast to monocytes, the ratio of neutrophils:T cells *in vivo* increased 20 times 1h after PC liposome administration (Figure 2i). An influx of neutrophils was also observed when PBS was administered *in vivo*, but with a reduced magnitude (Figure S4b). Although the percentage of neutrophils with PC liposomes was similar *in vivo* and *ex vivo* (Figure 2g), the large increase in the number of neutrophils after injection (Figure 2i) combined with the small increase in number of PC liposomes associated per neutrophil (Figure 2h) increased the total association of PC liposomes with neutrophils by 360 times (Figure 2j). Even though the number of PC liposomes associated per neutrophil is significantly lower than per monocyte ($p < 0.0001$), the decrease in monocytes and increase in neutrophils means that total association of PC liposomes with neutrophils *in vivo* is higher than monocytes, the opposite to what is observed *ex vivo* (Figures 2e, j).

The association of PC liposomes to B cells, like neutrophils, was also much lower than monocytes (Figures 2k-m). Unlike monocytes and neutrophils, the association of PC liposomes to B cells was slightly (3x) higher *in vivo* than *ex vivo* (Figure 2l). There was no significant change in the relative number of B cells after the *in vivo* administration of PC liposome (Figure 2n) or PBS (Figure S4c). Overall, the total association of PC liposomes with B cells was similar *in vivo* and *ex vivo* (Figure 2o).

PC liposome association with T cells, NK cells and eosinophils was low (Figure S5). The total association of PC liposomes to these cells was lower than for monocytes, neutrophils and B cells (Figure S5c, h, m vs Figure 2e, j, o).

Association of PEG-liposomes with immune cells in blood

The same *in vivo* and *ex vivo* experiments were also performed with PEG-liposomes. As observed with PC liposomes, PEG-liposomes showed high levels of association with monocytes (**Figure 3a-b**). Similar to the trend observed for PC liposomes, the number of PEG-liposomes associated per monocyte was 2.5x lower *in vivo* than *ex vivo* (Figure 3c). There was a more pronounced decrease in the monocytes:T cell ratio after *in vivo* administration of PEG-liposomes compared to PC liposomes ($p < 0.05$, Figure 3d vs Figure 2d). The reduced number of circulating monocytes combined with lower PEG-liposome association per monocyte resulted in 90x lower total association of PEG-liposomes *in vivo* compared to *ex vivo*. Consequently, the total association of PEG-liposomes to monocytes was 20x lower than PC liposomes *in vivo* ($p < 0.05$, Figure 3e vs Figure 2e).




Figure 3. Association of PEGylated liposomes with (a- e) monocytes, (f- j) neutrophils and (k- o) B cells. (a, f, k) Representative overlay histograms of control (green), ex vivo (red) and in vivo (blue) experiments. (b,g,l) Percentage of NP+ cells. (c, h, m) Corrected geometric mean fluorescent intensity (MFI) of sample minus the average MFI of the PBS. (d, i, n) Proportion of cells to T cells before and after administration of substances. (e, j, o) Total association of nanoparticles associated with the cells between *ex vivo* and *in vivo* experiments. Bars depict mean values. * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$

Similar to PC liposomes, at a cellular level, PEG-liposomes showed significantly lower association to neutrophils than monocytes both *in vivo* and *ex vivo* ($p < 0.0001$, Figure 3f-h). The number of neutrophils also increased following *in vivo* administration (Figure 3i), however the increase was less than observed for PC liposomes (2x lower, Figure 2i) and the PBS control group (2x lower, Figure S4). Compared to PC liposomes, the total association of PEG-liposomes with neutrophils *in vivo* was 4x lower ($p < 0.01$, Figure 3j vs Figure 2j).

The association of PEG-liposomes with B cells was similar *in vivo* and *ex vivo* (Figure 3k-m), in contrast to PC liposomes where association was significantly higher *in vivo* (Figure 3m vs Figure 2m). The number of B cells was similar after injection (Figure 3n), and the total association of PEG-liposomes with B cells was similar *in vivo* and *ex vivo* (Figure 3o). Total association of PEG-liposomes with B cells *in vivo* was 3x lower than PC-liposomes. The total association of PEG-liposome to T cells, NK cells and eosinophils was also low *in vivo* (**Figure S6**).

Discussion

Blood is the first point of contact when nanoparticles are administered intravenously. The complex and dynamic nature of the *in vivo* environment means simple *in vitro* studies, such as incubating nanoparticles with primary monocytes and macrophages, only give limited insight into the interactions that can occur.^[19] Currently, the most robust way to evaluate bio-nano interactions with blood is to use an *ex vivo* whole blood assay.^[12] However *in vivo*, nanoparticles are subjected to a range of additional cellular and non-cellular factors, such as complex mixing as blood moves through the vasculature, cell-cell/ cell-extracellular matrix interactions, and changes in blood immune cell

This article is protected by copyright. All rights reserved.

homeostasis, which can all influence how immune cells interact with the nanoparticles. *Ex vivo* and *in vitro* assays cannot take into account these environmental factors. To this end, we have developed a method to quantify nanoparticle association with immune cells in blood *in vivo*, and compared the patterns of association with *ex vivo* association using whole blood.

In this study, we selected PC and PEG-liposomes which are similar in size and charge to the clinical formulations (without doxorubicin) of Myocet and Doxil respectively.^[20] Doxil is a widely used formulation of doxorubicin to treat solid and hematological cancers.^[21] Doxil presents a lower clearance rate and longer half-life (55 h) compared to free doxorubicin (<1 h) and the analogous non-pegylated liposome formulation, Myocet (2-3 h).^[22, 23] The increased half-life of Doxil causes side effects such as skin reactions and hypersensitivity, hence, for some cancers (e.g. metastatic breast cancer), Myocet is preferred as minimizes these side effects.^[24]

Significant differences were observed with the association of liposomes to monocytes *in vivo* and *ex vivo*. For both PC liposomes and PEG-liposomes, the MFI of monocytes (and thus the number of nanoparticles per monocyte) *in vivo* was less than half the signal observed *ex vivo*. Furthermore, there was a two-fold reduction in circulating monocytes after intravenous administration of PC liposomes or the PBS control. PEG-liposomes caused an even greater 40- fold decrease in the number of circulating monocytes. The decrease in number of circulating monocytes may be due to adherence of the monocytes to the endothelium, where the cells undergo a phenotypic change and extravasate to the tissues.^[25] The combination of lower number of liposomes per monocyte, and lower number of monocytes in circulation means that for PEG liposomes the total association to monocytes *in vivo* was less than 2% of the total association observed *ex vivo* and for PC-liposomes it was 20%. This trend is highlighted in **Figure 4**, which compares the total association of liposomes to the different cell populations, and highlights the differences observed in the NIVIA and *ex vivo* assays. The reduced

total liposome association with monocytes *in vivo* suggests that the *ex vivo* assay over-estimates the role that monocytes have on liposome clearance.




Figure 4. Summary of mean total association of liposomes with each immune cell subset.

Conversely, the increased total association with neutrophils *in vivo* was underestimated in the *ex vivo* assay. Although the number of liposomes per neutrophil were significantly lower than the number of liposomes per monocyte (both *ex vivo* and *in vivo*), a 10-20 fold increase in the number of neutrophils after intravenous injection altered the total liposome association with neutrophils substantially, to become more significant than the total association with monocytes. Association of PEG-liposomes with neutrophils *in vivo* accounted for 40% of the total association with blood cells, compared to 1% *ex vivo*. Similarly, association of PC liposomes with neutrophils *in vivo* account for 45% of the total association with blood cells, compared to <1% *ex vivo* (Figure 4). Neutrophils in blood are a transient population and represent only 1-2 % of the total pool of cells available in mice.^[26] The remaining neutrophils are stored within the bone marrow.^[27, 28] Although neutrophils are more abundant in human blood compared to mice, the vast majority of these cells are stored in the bone marrow.^[29] Neutrophils have a circulation half-life of 6-12 h.^[30-32] This short half-life and the capacity to rapidly mobilize cells from the bone marrow enables rapid changes in concentration in blood. Injection of

nanoparticles into mice and, to a lesser extent PBS, caused a large influx of neutrophils into blood, and the sequestration of 65x more PC liposomes and 20x PEG-liposomes than would be suggested by the *ex vivo* assays. The NIVIA assay demonstrated the potentially significant role that neutrophils can play in liposome clearance *in vivo*, which is not possible to observe with *ex vivo* assays.

Although the change in balance of monocyte and neutrophil in peripheral blood is consistent with previous septic studies that investigated infection and inflammation,^[33-35] endotoxin levels in the PC liposomes, PEG-liposomes and PBS were below immunostimulatory levels. We speculate that the observed change in homeostasis may have been a stress response associated with handling of mice for injection.^[36, 37] This may have triggered the extravasation of monocytes from blood and recruitment of neutrophils into blood^[38, 39], altering the homeostasis of monocytes and neutrophils *in vivo*. External factors such as stress that alter blood homeostasis will also be common in clinical settings.

B cells are a dynamic population that naturally recirculate between the lymph and blood.^[40] We did not observe a large change in the proportion of B cells, suggesting the equilibrium between lymph and blood was not affected by either the intravenous injection or the presence of liposomes. Although the number of particles associating per cell was relatively low, by virtue of their abundance, B cells contributed substantially to nanoparticle sequestration. The association of PC liposomes was slightly higher *in vivo* compared to *ex vivo* as indicated by the MFI, however the total association to B cells *in vivo* and *ex vivo* was not significantly different for both types of particles. The association of PC liposomes with B cells is consistent with studies involving other particle systems.^[32, 41] *Ex vivo*, association of PC liposomes with monocytes and B cells were the dominant interactions, however *in vivo*, association with neutrophils and B cells were dominant.

In the NIVIA assay, liposomes in circulation will be exposed to phagocytic cells within the sinusoidal endothelium in the liver and spleen, which can remove liposomes from circulation. The Kupffer cells in the liver and red pulp macrophages in the spleen are more abundant than blood monocytes and are effective at removing nanoparticles from blood. Moreover, other cells such as the liver sinusoidal endothelial cells can also remove large numbers of nanoparticles from circulation. Therefore, we would anticipate that total association of liposomes with blood cells *in vivo* would be lower than *ex vivo*, due to sequestration of nanoparticles in these other organs. Figure 4 shows this trend holds for PEG liposomes, however for PC liposomes, total association was higher *in vivo*. The increased total association for PC liposomes *in vivo* can be accounted by the significant increase in the number of circulating neutrophils, and if neutrophils are excluded, total association of PC liposomes *in vivo* is ~30% lower than *ex vivo*.

PEG-liposomes showed 3 to 5 x lower total association compared to PC liposomes for phagocytes (monocytes, neutrophils and eosinophils) and lymphocytes (B cells and NK cells). This demonstrates that as expected, PEGylation of liposomes is able to mask detection from these immune cells to some extent *in vivo*.^[42, 43]

Human and mouse blood is composed of the same types of cells, however there are differences in the relative proportions of each subset and minor variations in the phenotypes of cells.^[44] Neutrophils are the most abundant subset in humans, while in mice, lymphocytes are more abundant.^[27] Despite these differences, there is a high level of genetic conservation between the species, so the behavior of individual subsets can be inferred from mice to humans.^[44] *Ex vivo* analysis of nanoparticle-immune cell association enables interactions with human cells to be directly investigated. However, as highlighted in this paper, only the *in vivo* assay can account for myriad factors that can influence bio-nano interactions *in vivo*.

Conclusion

In summary, we developed an *in vivo* assay that provides new insights into the interactions of nanoparticles with immune cells. We found that existing *ex vivo* blood assays can underestimate the role of neutrophils in liposome clearance, with neutrophils showing > 50 times higher total association of liposomes *in vivo* compared to *ex vivo*. *In vivo*, the major factor contributing to significantly higher total association with neutrophils was an increase in the number of circulating neutrophils. The increased role of neutrophils observed *in vivo* with the NIVIA assay is likely to be relevant for a range of other nanoparticles, such as synthetic/natural polymer-based systems and inorganic particles. Furthermore, while monocytes had a higher number of liposomes bound per cell than any other cell type, *in vivo* we observed both a decrease in the number of monocytes in circulation, as well as a decrease in number of liposomes associated per monocyte. This led to significantly lower total association to monocytes *in vivo* than *ex vivo*. While monocytes and B cells play a dominant role in nanoparticle interactions *ex vivo*, interaction with neutrophils and B cells dominate *in vivo*.

The *in vivo* environment has mechanical, biological and structural elements that cannot be faithfully replicated *ex vivo*. When the full complexity of these factors are taken into consideration more reliable predictions of *in vivo* nanoparticle behavior can be made. *Ex vivo* methods of characterizing novel nanoparticles do not give a complete picture of the complex *in vivo* nanoparticle-immune cell interactions. The NIVIA assay offers a valuable new tool to characterize a wide range of nanoparticles and gives detailed information about their interactions with immune cells. The information gained from the NIVIA assay significantly improves our understanding of nanoparticle interactions with the

biological environment and has the potential to be an essential preclinical test for characterizing the *in vivo* behavior of novel nanoparticles.

Materials and Experimental Methods

Materials

DBCO reactive fluorescent liposomes with DiD dye were purchased from Encapsula NanoScience LLC (TN, USA). The product numbers of PEG-liposomes and PC-liposomes were IMF321 and IMF3261 respectively. They were received at stock concentration of 15.98 mg/ml for PEG liposomes and 14.84 mg/ml for PC-liposomes. The composition of PEG-liposomes were 57 mol % hydrogenated soy phosphatidylcholine, 38 mol % cholesterol and 5 mol % DSPE-PEG(2000) while PC-liposomes were 68.5 mol % L-alpha-Phosphatidylcholine, 30 mol % cholesterol and 1.5 mol % DBCO PE. The antibodies used in the cocktail to phenotype immune cell subsets were purchased from BD Biosciences (USA).

Liposome characterization

Stock unmodified and PEG-liposomes were diluted in PBS at a dilution of 1 in 50 000 and particle size was measured by Nanoparticle Tracking Analysis software using NanoSight NS3000 System (Malvern Technologies, Malvern, UK). Each liposome was analyzed under constant flow conditions (flow rate = 40) and 5 x 60 s videos were captured with camera level of 13. Data was analyzed with NTA 3.4 software with detection threshold of 8. Liposome size distribution was determined by D10, D50 and D90 measurements from the NanoSight. Stock liposomes were diluted 1 in 50 000 with 10 mM phosphate buffer (pH 7) and the zeta potential of PC-liposomes and PEG-liposomes were

measured thrice with Zetasizer Nano ZS (Nano ZS, Malvern, UK) using disposable folded capillary zeta cell.

Fluorescence measurements

The fluorescence intensities of DiD in the unmodified and PEG-liposomes were measured with spectroscopy (RF-5301PC, Shimadzu). The wavelength was excited at 646 nm and emitted at the range from 656 nm to 700 nm with 1 nm sampling interval. As the fluorescence intensity of PEG-liposomes was 59% higher than unmodified liposomes, the MFI of unmodified liposomes experiments were multiplied by 1.59.

In vivo blood studies

Adult C57BL/6 mice were purchased from Monash Animal Research Platform (MARF, Clayton). All experiments were approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee. Mice (18 g – 25 g) were injected intravenously at a dose of 7 mg/kg with either PEGylated (n = 8) or uncoated (n = 4) liposomes (equivalent of clinical dose of 20 mg/m² of Doxorubicin based on body surface area^[53]) (Encapsula NanoScience ImmunoFluor-DBCO, IMF321 [PEG-liposome], IMF3261 [PC-liposome]) in 200 μ L PBS and blood was collected into a K₂EDTA-coated microtainer (BD Biosciences) after 1 h. A 1 h timepoint was considered optimal to observe differences in any immune cell association for PC- and PEG- liposomes, consistent with particle half-life's, 3 h and 55 h, respectively. 200 μ L of Phosphate-Buffered Saline (PBS, Gibco) was injected intravenously in the control group (n = 5).

The *in vivo* liposome dose was chosen based on the therapeutic dose of 2 mg/mL Doxil used clinically (20 mg/m² intravenously injected).^[24, 25] Assuming that the average surface area:weight ratio of a

This article is protected by copyright. All rights reserved.

mouse is 0.35 mL/kg, the final dose concentration of liposome used was 7 mg/kg.^[31] The final dose volume of PEG-liposomes was multiplied by 0.93 so that the amount of liposomes injected was similar to PC liposomes. The equivalent *ex vivo* dose was calculated based on a total blood volume of 7% of the mouse body weight.^[26] The level of endotoxin in both liposome formulations was 0.8 – 1 EU/mL as from manufacturer and not expected to cause an immune activation.

Ex vivo blood studies

Mice were weighed to estimate the total blood volume. The total blood volume was assumed to be 7% of total body weight of the mouse (70 mL/kg) and the dose equivalent for 100 μ L of blood collected was calculated. Whole blood was collected from adult C57BL/6 mice via cardiac puncture using a 27 g needle into K₂EDTA coated microtainer (BD Biosciences). The blood was pre-heated in a thermomixer for 5 mins at 37 °C. PEG- (n = 7) or PC- liposomes (n = 7) or PBS (n = 5) were added to the blood and incubated for 1 h at 37 °C. Samples were vortexed gently for 1 sec at 15 min intervals.

Immunophenotyping and Blood processing

To identify immune cells that are interacting with the DiD- labeled nanoparticles in the blood, freshly collected whole blood was labelled with a cocktail of antibodies (Table S1), including Brilliant Stain buffer (BD) (1:2 dilution) and Fc blocker (1: 100 dilution) for 1 h at room temperature. Erythrocytes in the blood were then lysed with ACK lysis buffer (Gibco) for 5 min at room temperature. Hanks' Balanced Salt Solution (HBSS) was added to stop the lysis and centrifuged at 500 x g for 7 min. The pellet was washed twice with 1% PBS/EDTA (pH 7.4) and acquired with a Stratadigm S1000EXi flow cytometer.

Flow cytometry

Bio-nano interactions were analyzed and quantified using FlowJo v10.5.3. Compensation for spectral overlap of fluorochrome-conjugated antibodies was calculated from single stained controls prepared with ultraComp eBeads (ThermoFisher Scientific) according to manufacturer's instructions. The immunophenotyping gating strategy is outlined in Figure S2. As the frequency of dendritic cells was low, dendritic cells were excluded from the analysis. The mean fluorescent intensity (MFI) of liposome fluorescence, DiD was derived from the geometric mean of DiD in each cell population. To adjust for difference in fluorescence between the two types of liposomes as measured by spectroscopy (RF-5301PC, Shimadzu, activation at 663 nm), the MFI of unmodified liposomes were multiplied by 1.59. The average background fluorescence derived from the PBS controls was subtracted from MFI of each cell population. The autofluorescence of the control cells *ex vivo* (treated with PBS only) and *in vivo* (injected with PBS only) were similar, so only the *in vivo* control samples are shown in the representative histograms.

Statistical analysis

Statistical tests were performed with Prism 8 (GraphPad Software, La Jolla, USA). All groups were assumed to follow a parametric distribution and unpaired t tests were performed to determine statistical significance between two groups. A $p < 0.05$ was determined to be statistically significant.

All data are presented with mean. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

This research was supported by a National Health and Medical Research Council Project Grant (1129672, A.P.R.J.) and Career Development Fellowship (1141551, A.P.R.J.) as well as the Australian Research Council through the Centre of Excellence in Convergent Bio-Nano Science and Technology (A.P.R.J.). A.P.R.J. is also supported through the Monash University Lar-kin's Fellowship Scheme.

Received: ((will be filled in by the editorial staff))

Revised: ((will be filled in by the editorial staff))

Published online: ((will be filled in by the editorial staff))

References

- [1] Y. Barenholz, *J Control Release* **2012**, *160*, 117-34.
- [2] A. S. Thakor, J. V. Jokerst, P. Ghanouni, J. L. Campbell, E. Mittra, S. S. Gambhir, *J Nucl Med* **2016**, *57*, 1833-1837.
- [3] A. E. Gregory, R. Titball, D. Williamson, *Front Cell Infect Microbiol* **2013**, *3*, 13-13.
- [4] J.-F. Jin, L.-L. Zhu, M. Chen, H.-M. Xu, H.-F. Wang, X.-Q. Feng, X.-P. Zhu, Q. Zhou, *Patient Prefer Adherence* **2015**, *9*, 923-942.
- [5] V. H. Nguyen, B.-J. Lee, *Int J Nanomedicine* **2017**, *12*, 3137-3151.
- [6] M. A. Dobrovolskaia, A. K. Patri, J. Zheng, J. D. Clogston, N. Ayub, P. Aggarwal, B. W. Neun, J. B. Hall, S. E. McNeil, *Nanomedicine* **2009**, *5*, 106-17.
- [7] G. Maiorano, S. Sabella, B. Sorce, V. Brunetti, M. A. Malvindi, R. Cingolani, P. P. Pompa, *ACS Nano* **2010**, *4*, 7481-91.
- [8] L. Guerrini, R. A. Alvarez-Puebla, N. Pazos-Perez, *Materials (Basel)* **2018**, *11*,
- [9] H. L. Kutscher, G. D. Morse, P. N. Prasad, J. L. Reynolds, *Pharm Res* **2019**, *36*, 44-44.
- [10] C. Vogt, M. Pernemalm, P. Kohonen, S. Laurent, K. Hultenby, M. Vahter, J. Lehtiö, M. S. Toprak, B. Fadeel, *PLOS ONE* **2015**, *10*, e0129008.

- [11] N. Oh, J.-H. Park, *Int J Nanomedicine* **2014**, *9 Suppl 1*, 51-63.
- [12] R. De Rose, A. N. Zelikin, A. P. R. Johnston, A. Sexton, S.-F. Chong, C. Cortez, W. Mulholland, F. Caruso, S. J. Kent, *Advanced Materials* **2008**, *20*, 4698-4703.
- [13] N. B. Shah, G. M. Vercellotti, J. G. White, A. Fegan, C. R. Wagner, J. C. Bischof, *Mol Pharm* **2012**, *9*, 2146-55.
- [14] I. Constantinescu, E. Levin, M. Gyongyossy-Issa, *Artif Cells Blood Substit Immobil Biotechnol* **2003**, *31*, 395-424.
- [15] C. A. Fromen, W. J. Kelley, M. B. Fish, R. Adili, J. Noble, M. J. Hoenerhoff, M. Holinstat, O. Eniola-Adefeso, *ACS Nano* **2017**, *11*, 10797-10807.
- [16] R. Münter, K. Kristensen, D. Pedersbæk, J. B. Larsen, J. B. Simonsen, T. L. Andresen, *Nanoscale* **2018**, *10*, 22720-22724.
- [17] T. J. H. University, Animal Care and Use Committee,
<http://web.jhu.edu/animalcare/procedures/mouse.html#additional>, accessed: Oct, **2020**.
- [18] K. Prame Kumar, A. J. Nicholls, C. H. Y. Wong, *Cell Tissue Res* **2018**, *371*, 551-565.
- [19] M. Bartneck, H. A. Keul, S. Singh, K. Czaja, J. Bornemann, M. Bockstaller, M. Moeller, G. Zwadlo-Klarwasser, J. Groll, *ACS Nano* **2010**, *4*, 3073-3086.
- [20] U. Bulbake, S. Doppalapudi, N. Kommineni, W. Khan, *Pharmaceutics* **2017**, *9*,
- [21] I. Sousa, F. Rodrigues, H. Prazeres, R. T. Lima, P. Soares, *Cancer Chemother Pharmacol* **2018**, *82*, 741-755.
- [22] A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, Y. Barenholz, *Cancer Research* **1994**, *54*, 987.

- [23] A. A. Gabizon, *Cancer Invest* **2001**, *19*, 424-36.
- [24] M. E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, P. Tomczak, S. P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler, *Ann Oncol* **2004**, *15*, 440-9.
- [25] A. R. Schenkel, Z. Mamdouh, W. A. Muller, *Nat Immunol* **2004**, *5*, 393-400.
- [26] C. L. Semerad, F. Liu, A. D. Gregory, K. Stumpf, D. C. Link, *Immunity* **2002**, *17*, 413-23.
- [27] R. Boxio, C. Bossenmeyer-Pourie, N. Steinckwich, C. Dournon, O. Nusse, *J Leukoc Biol* **2004**, *75*, 604-11.
- [28] K. E. O'Connell, A. M. Mikkola, A. M. Stepanek, A. Vernet, C. D. Hall, C. C. Sun, E. Yildirim, J. F. Staropoli, J. T. Lee, D. E. Brown, *Comp Med* **2015**, *65*, 96-113.
- [29] C. Rosales, *Frontiers in Physiology* **2018**, *9*,
- [30] S. von Vietinghoff, K. Ley, *J Immunol* **2008**, *181*, 5183-8.
- [31] M. Casanova-Acebes, C. Pitaval, L. A. Weiss, C. Nombela-Arrieta, R. Chèvre, A. G. N, Y. Kunisaki, D. Zhang, N. van Rooijen, L. E. Silberstein, C. Weber, T. Nagasawa, P. S. Frenette, A. Castrillo, A. Hidalgo, *Cell* **2013**, *153*, 1025-35.
- [32] J. M. Adrover, J. A. Nicolás-Ávila, A. Hidalgo, *Trends Immunol* **2016**, *37*, 334-345.
- [33] B. Thaler, P. J. Hohensinner, K. A. Krychtiuk, P. Matzneller, L. Koller, M. Brekalo, G. Maurer, K. Huber, M. Zeitlinger, B. Jilma, J. Wojta, W. S. Speidl, *Scientific reports* **2016**, *6*, 30162-30162.
- [34] G. Fingerle, A. Pforte, B. Passlick, M. Blumenstein, M. Strobel, H. W. Ziegler-Heitbrock, *Blood* **1993**, *82*, 3170-6.
- [35] M. Mandl, S. Schmitz, C. Weber, M. Hristov, *PLoS One* **2014**, *9*, e112140-e112140.

- [36] F. S. Dhabhar, W. B. Malarkey, E. Neri, B. S. McEwen, *Psychoneuroendocrinology* **2012**, *37*, 1345-1368.
- [37] L. M. Ince, J. Weber, C. Scheiermann, *Frontiers in Immunology* **2019**, *9*,
- [38] C. Auffray, D. Fogg, M. Garfa, G. Elain, O. Join-Lambert, S. Kayal, S. Sarnacki, A. Cumano, G. Lauvau, F. Geissmann, *Science* **2007**, *317*, 666-70.
- [39] D. Begandt, S. Thome, M. Sperandio, B. Walzog, *J Leukoc Biol* **2017**, *102*, 699-709.
- [40] J. P. Girard, C. Moussion, R. Förster, *Nat Rev Immunol* **2012**, *12*, 762-73.
- [41] J. J. Glass, D. Yuen, J. Rae, A. P. R. Johnston, R. G. Parton, S. J. Kent, R. De Rose, *Nanoscale* **2016**, *8*, 8255-8265.
- [42] Q. Yang, S. W. Jones, C. L. Parker, W. C. Zamboni, J. E. Bear, S. K. Lai, *Mol Pharm* **2014**, *11*, 1250-8.
- [43] C. D. Walkey, J. B. Olsen, H. Guo, A. Emili, W. C. Chan, *J Am Chem Soc* **2012**, *134*, 2139-47.
- [44] J. Mestas, C. C. W. Hughes, *The Journal of Immunology* **2004**, *172*, 2731-2738.

Y. R. Ong, R. De Rose, A.P.R. Johnston*

***In vivo* quantification of nanoparticle association with immune cell subsets in blood**

Clearance of nanoparticles from circulation in blood is a significant hurdle for the therapeutic application of novel nanomedicines. Here we developed a Nanoparticle In Vivo Immune-cell Association (NIVIA) assay that shows how the behavior of nanoparticles after intravenous injection is influenced by factors unique to the *in vivo* environment and cannot be replicated *ex vivo*.

